Board Director

Leyland-JonesBrian Leyland-Jones, MB BS, BSc (1st Class Hons) SMH (Imperial), LRCP, MRCS, PhD, FACP, FRCPC.

A fellow of the American College of Physicians and a recipient of numerous research grants, Dr. Leyland-Jones has served as principal, co-principal, and co-investigator on more than 100 clinical studies and was instrumental in the development of numerous cancer treatments, including Herceptin (trastuzumab) and Taxol (paclitaxel). He has authored and co-authored more than 243 peer-reviewed articles and book contributions, 25 books and book chapters, 427 abstracts and 35 patents.

Dr. Leyland-Jones has served as an instrumental leader of three cancer centers and held positions as Founding Chair of Oncology and Director of the McGill University Comprehensive Cancer Centre; Director of the Winship Cancer Centre and Associate Vice-President of Health Sciences at Emory University; Vice President of the Molecular and Experimental Medicine Genomics Medicine Program at the Avera Cancer Institute. Additionally, he founded three companies including AKESOgen, Inc., Xanthus Pharmaceuticals Ltd., and Viviphi Ltd.

Dr. Leyland-Jones currently holds roles on several national and international boards including Chief Medical Officer and Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR); Chief Medical Officer of OTraces and the N OF 1 Mission; Asian Foundation for Cancer Research (AFCR); Non-Pareil; Parthen, Ratio and the WIN Consortium. He holds biochemistry, medical, and doctoral degrees from the University of London. Dr. Leyland-Jones completed residency training at London hospitals including Hammersmith, Brompton, and St. Bartholomew’s, as well as a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center.

He has held or holds Professorships at McGill University, Emory University, Stanford University and as well as Assistant Professorships at Memorial Sloan Kettering Cancer Center and Cornell University. He is a past Chief of Development Therapeutics at the National Cancer Institute (NCI) and the National Institute of Health (NIH).

Dr. Leyland-Jones also consults and speaks for institutions, universities, and events globally.